Related Experiment Video
Updated: Mar 2, 2026

03:55
Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
Published on: December 29, 2023
1.3K
Robot-assisted adrenalectomy: indications and drawbacks
C Nomine-Criqui1, A Germain2, A Ayav2
1Department of Digestive, Hepatobiliary, Endocrine, and Oncology Surgery, University of Lorraine, CHU Nancy-Brabois (Adultes), 54511, Vandoeuvre-Les-Nancy, France. c.nomine-criqui@chru-nancy.fr.
Updates in Surgery
|May 13, 2017
Summary
Robotic adrenalectomy offers benefits for complex cases like large tumors, but cost-effectiveness requires more clinical data. This review compares robotic to laparoscopic adrenalectomy for adrenal tumors.
Area of Science:
- Urology
- Surgical Oncology
- Minimally Invasive Surgery
Background:
- Adrenal tumors range from benign adenomas to malignant carcinomas and pheochromocytomas.
- Laparoscopic adrenalectomy is the standard surgical approach, with limited comparative data against open surgery.
- Robotic adrenalectomy is emerging, but its clinical benefits and cost-effectiveness are under investigation.
Purpose of the Study:
- To review current data on robotic transperitoneal adrenalectomy.
- To compare robotic adrenalectomy with conventional laparoscopic adrenalectomy.
- To evaluate indications, advantages, and limitations of robotic adrenalectomy.
Main Methods:
- Literature review of existing studies on robotic adrenalectomy.
- Comparison of robotic versus laparoscopic adrenalectomy outcomes.
- Analysis of clinical data regarding tumor size, type, and surgical complexity.
Main Results:
- Robotic systems may be advantageous for complex adrenalectomies, including large tumors and bilateral procedures.
- Potential benefits include decreased hospital stay and improved surgeon ergonomics.
- High costs remain a significant drawback, lacking robust clinical data to justify the expense.
Conclusions:
- Robotic adrenalectomy shows promise for specific challenging cases.
- Further clinical trials are needed to validate cost-effectiveness and long-term outcomes.
- The current business model for robotic surgery may be counterproductive without strong supporting evidence.

